The development of neutralizing antibodies against SARS-CoV-2 and their common features

Liu Daisy Liu; Chaoyang Lian; Leng-Siew Yeap; Fei-Long Meng

doi:10.1093/jmcb/mjaa070

The development of neutralizing antibodies against SARS-CoV-2 and their common features

J Mol Cell Biol. 2020 Nov 25;12(12):980-986. doi: 10.1093/jmcb/mjaa070.

Authors

Liu Daisy Liu¹, Chaoyang Lian², Leng-Siew Yeap², Fei-Long Meng¹

Affiliations

¹ State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences; University of Chinese Academy of Sciences, Shanghai 200031, China.
² Shanghai Institute of Immunology, State Key Laboratory of Oncogenes and Related Genes, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a great demand for effective therapies for the prevention and treatment of COVID-19. Developing therapeutic neutralizing antibodies (NAbs), which could block viral infection, is such a promising approach, as NAbs have been successfully applied to the treatment of other viral infections. The recent advances of antibody technology have greatly accelerated the discovery of SARS-CoV-2 NAbs, and many of which are now actively tested in clinical trials. Here, we review the approaches applied for SARS-CoV-2 NAb development, and discuss the emerging technologies underlining the antibody discovery. We further summarize the common features of these antibodies including the shared neutralizing epitopes and sequence features.

Keywords: COVID-19; RBD; SARS-CoV-2; epitope; neutralizing antibody.

Publication types

Review

MeSH terms

Animals
Antibodies, Monoclonal, Humanized / immunology
Antibodies, Monoclonal, Humanized / isolation & purification
Antibodies, Monoclonal, Humanized / therapeutic use
Antibodies, Monoclonal, Murine-Derived / immunology
Antibodies, Monoclonal, Murine-Derived / isolation & purification
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antibodies, Neutralizing / immunology
Antibodies, Neutralizing / isolation & purification
Antibodies, Neutralizing / therapeutic use*
Antibodies, Viral / immunology
Antibodies, Viral / isolation & purification
Antibodies, Viral / therapeutic use*
Antibody Diversity
COVID-19 / immunology*
COVID-19 / therapy*
COVID-19 / virology
Drug Discovery
Epitopes / chemistry
Epitopes / immunology
Humans
Mice
Models, Molecular
Pandemics
SARS-CoV-2 / immunology*
Spike Glycoprotein, Coronavirus / chemistry
Spike Glycoprotein, Coronavirus / immunology

Substances

Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Murine-Derived
Antibodies, Neutralizing
Antibodies, Viral
Epitopes
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2